Table 1 Case distribution
Variables | All cases n = 475 | TP53-aberrant n = 80 (17%) | TP53-normal n = 395 (83%) |
|---|---|---|---|
Age at diagnosis, years | |||
<60 | 247 (52%) | 28 (35%) | 219 (55%) |
≥60 | 228 (48%) | 52 (65%) | 176 (44%) |
BMI, kg/m 2 | |||
<25 | 279 (59%) | 56 (70%) | 223 (57%) |
≥25 | 195 (41%) | 23 (29%) | 172 (43%) |
NA | 1 (0%) | 1 (1%) | 0 (0%) |
FIGO stage (2008) | |||
I | 355 (75%) | 48 (60%) | 307 (78%) |
II | 25 (5%) | 4 (5%) | 21 (5%) |
III | 60 (13%) | 13 (16%) | 47 (12%) |
IV | 35 (7%) | 15 (19%) | 20 (5%) |
FIGO grade | |||
G1 | 327 (69%) | 31 (39%) | 296 (75%) |
G2 | 88 (18%) | 18 (22%) | 70 (18%) |
G3 | 60 (13%) | 31 (39%) | 29 (7%) |
Lymphovascular invasion | |||
Absent | 311 (66%) | 34 (43%) | 277 (70%) |
Present | 135 (28%) | 30 (37%) | 105 (27%) |
NA | 29 (6%) | 16 (20%) | 13 (3%) |
Myometrial invasion | |||
<50% | 295 (62%) | 32 (40%) | 263 (67%) |
≥50% | 149 (31%) | 31 (39%) | 118 (30%) |
NA | 31 (7%) | 17 (21%) | 14 (3%) |
Hysterectomy | |||
Yes | 445 (94%) | 63 (79%) | 382 (97%) |
No | 30 (6%) | 17 (21%) | 13 (3%) |
Lymphadenectomy | |||
Yes | 221 (47%) | 33 (41%) | 188 (48%) |
No | 254 (53%) | 47 (59%) | 207 (52%) |
Adjuvant therapy | |||
Yes | 148 (31%) | 31 (39%) | 117 (30%) |
No | 317 (67%) | 42 (52%) | 275 (69%) |
NA | 10 (2%) | 7 (9%) | 3 (1%) |
Neo-adjuvant therapy | |||
Yes | 53 (11%) | 23 (29%) | 30 (8%) |
No | 422 (89%) | 57 (71%) | 365 (92%) |
Recurrence | |||
Yes | 81 (17%) | 32 (40%) | 49 (12%) |
No | 394 (83%) | 48 (60%) | 346 (88%) |
Death | |||
Yes | 69 (15%) | 29 (36%) | 40 (10%) |
No | 406 (85%) | 51 (64%) | 355 (90%) |
